Skip to main content
. Author manuscript; available in PMC: 2011 Aug 1.
Published in final edited form as: Obstet Gynecol. 2010 Aug;116(2 Pt 1):365–373. doi: 10.1097/AOG.0b013e3181e93330

Table 1.

Baseline characteristics of 1443 women with complex hyperplasia with and without atypia by progestin exposure during the study

Complex N=1201 Atypia N=242

No Progestin
N=164
Progestin >
14d
N=1037
No Progestin
N=62
Progestin >
14d
N=180
Age (years)
 <39 17(10.4) 79(7.6) 4(6.5) 13(7.2)
 40-49 50(30.5) 314(30.3) 16(25.8) 35(19.4)
 50-59 59(36.0) 415(40.0) 16(25.8) 64(35.6)
 60-69 23(14.0) 145(14.0) 15(24.2) 43(23.9)
 ≥70 15(9.1) 84(8.1) 11(17.7) 25(13.9)
Caucasian1 128(82.1) 907(89.3) 55(90.2) 156(90.2)
Diabetes1 13(8.3) 82(8.1) 6(9.8) 21(12.1)
Breast/Colon
Cancer1
15(9.1) 23(2.2) 3(4.8) 13(7.2)
Current Smoker1 12(8.3) 117(12.1) 9(15.5) 21(12.6)
BMI (kg/m2)1
 <25 42(27.5) 329(33.1) 19(31.2) 56(32.2)
 25 – 29.9 32(20.9) 260(26.2) 14(23.0) 39(22.4)
 ≥30 79(51.6) 404(40.7) 28(45.8) 79(45.4)
Nulliparous1 32(20.5) 158(15.6) 13(21.3) 32(18.5)
Oral contraceptive2 4(2.4) 13(1.3) 1(1.6) 1(0.6)
Estrogen +
Progestin2,3
0(0) 165(15.9) 4(6.5) 24(13.3)
Unopposed
Estrogen2,4
6(3.7) 143(13.8) 7(11.3) 28(15.6)
Progestin only2 0(0) 11(1.1) 0(0) 4(2.2)
Index biopsy year
 1985 – 1989 32(19.5) 233(22.5) 19(30.7) 56(31.1)
 1990 – 1994 37(22.6) 364(35.1) 14(22.6) 52(28.9)
 1995 – 1999 46(28.0) 291(28.0) 19(30.7) 42(23.3)
 2000 – 2005 49(29.9) 149(14.4) 10(16.1) 30(16.7)
1

Missing data. d = days. BMI = body mass index.

2

Dispensed for at least 2 months in the 6 months preceding diagnosis of endometrial hyperplasia.

3

Estrogen + progestin = postmenopausal hormone therapy (the progestin was dispensed for at least 1/3 of the time that the estrogen was dispensed).

4

Unopposed Estrogen = postmenopausal hormone therapy (estrogen alone or estrogen plus progestin where progestin was dispensed less than 1/3 of the time that estrogen was dispensed).